T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD - Villingen-Schwenningen, Germany
EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
Video navigation menu
- Is reducing HbA1c really succesful in diabetes? 1:47
- Cardiovascular outcomes trials 3:53
- Underlying mechanisms of CV benefits with GLP-1RAs 6:48
- New recommendations for T2DM patients 9:11
This lecture by prof. Stephan Jacob was part of a CME accredited symposium "The preventive challenge in diabetes & CVD - A multidisciplinary approach"
Prof. Stephan Jacob, endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.